Key points from article :
OneSkin began life validating effectiveness of skincare products.
Developed its own skin aging clock based on skin-specific epigenetic DNA markers.
Screened a synthetic library for antimicrobial peptides.
From an initial list of 200 AMPs, the team looked at the four compounds .
Generated 800 novel sequences led to the lead compounds, OS-1 and OS-2.
These two peptides had the most potential for tackling senescence (by 25-50%) caused by aging UV light and genotoxic stress.
Inability to reduce the growth of some bacteria strains indicate that the compounds are not anti-microbial.
OneSkin is topically applied and classed as a cosmetic.
Safety studies performed to assess skin irritation, corrosion and sensitisation.
OneSkin’s patented compound OS-1 tackles senescent skin cells.
Product launches in October.
OS-1 has also extended the median lifespan of C. Elegans by over 20%.
Carolina Reis Oliveria, CEO, confirmed company has pre-seed funding from Indiebio & SOSV and seed round funding from 2Future.
